News

AI stocks tumble on safety warnings. How to proceed — including 2 names on our shopping list

Jim Cramer offers a roadmap to navigate Monday's sell-off in AI stocks.

Should You Buy Newmont Stock After a 60% Rally in a Year?

NEM, KGC, AEM, B

Newmont's 60% rally reflects strong earnings and cash flow, but lower production, higher costs and falling estimates cloud its outlook.

AI models are becoming the ‘most potent cyber weapon’ ever created, Cohere CEO says

Cybersecurity concerns are feeding a broader AI safety debate, with industry leaders calling for measures to slow frontier AI development.

AI safety fears, rising oil prices, a big season for prediction markets and more in Morning Squawk

Here are five key things investors need to know to start the trading day.

Amazon pauses operations with 21 Air after Miami cargo plane crash

AMZN, AMZNN, AMZNCL, AMZD, AMZ, 1AMZN, 0R1O, 4AMZN, 0R1OL, AMZNUS, AMZNCL0, AMZNCL1, AMZN0, AMZN1

Amazon said on Sunday it was pausing operations with Miami-based 21 Air, the cargo carrier that operated the aircraft for Amazon Air that crashed in Miami.

Car ownership costs an average of $5,851 a year on top of auto loan payments, analysis finds

The cost of insurance, gas, and maintenance or repairs can add thousands of dollars a year to the price of owning a car.

Beat the Market the Zacks Way: FIGS, Microsoft, Amphenol in Focus

MSFT, ICE, ACN, PAYX, ADP, APH, CRL, FCFS, CACI, CIB, FIGS

FIGS, APH and MSFT post strong gains as Zacks upgrades and model portfolios spotlight stocks outperforming the broader market.

HOOD's August Metrics Strong Amid Mixed Trading Trends: What's Ahead?

HOOD, SCHW, IBKR

Robinhood's August metrics showed strong customer, asset and equity growth, while mixed trading trends kept transaction-based revenue risks in focus.

Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead

VRTX

Vertex’s Crinetics Deal Balances Growth with Integration RiskVertex Pharmaceuticals (NASDAQ:VRTX) is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and cell therapies among the company’s priorities, CEO and Pres

Why are there concerns AI could threaten humanity, and how real are they?

Existential fears about AI have once again reared their head - here's what you need to know.